Medical Ventures Corp.

Medical Ventures Corp.

September 10, 2007 09:00 ET

Medical Ventures Corp.: Pilot Study Suggests Metricath Is Effective in Renal Artery Procedures

Presentation features Metricath at NCVH conference

RICHMOND, BRITISH COLUMBIA--(Marketwire - Sept. 10, 2007) - MEDICAL VENTURES CORP. (TSX VENTURE:MEV) announces that its Metricath Libra® arterial and in-stent measurement system was shown in a pilot study to be effective for use in renal arteries, according to results shared at the New Cardiovascular Horizons (NCVH) conference in New Orleans.

The study, which measured stent dimensions in 20 renal lesions involving 16 patients, was designed to test whether optimal stent deployment during renal artery interventions can be achieved using the Metricath System. After stents were implanted according to typical procedures, researchers used Metricath to measure within the stents to determine if the desired expansion had been achieved. Additional steps were then taken to further expand under-expanded stents.

"Our results show that Metricath guidance resulted in us doing adjunctive intervention in 90 per cent, or 18 of 20 lesions," said Dr. Raed Aqel, the study's author and an interventional cardiologist at University of Alabama-Birmingham Hospital and Birmingham Veterans Affairs Medical Center. "Using Metricath disclosed a large proportion of under-deployed stents that had, visually, been deemed to be optimally deployed. Seeing the Metricath's indications of cross-sectional area and diameter allowed us to later optimize stent expansion by adjunctive balloon post-dilation at higher pressures and/or using bigger balloons."

"We learned in this study that relying on visual estimation and QA (quantitative angiography) alone for renal angiographic post-stenting can lead to over-estimation of actual renal artery stent size, especially at the lesion site. It is our estimation that optimizing renal artery stent size may reduce the rate of re-stenosis in patients who require renal artery stenting. The Metricath is a very user-friendly tool that allowed us to optimize renal artery stent size effectively, without adding more than 3 to 5 minutes to any procedure."

Renal artery stenosis is the narrowing of arteries leading to the kidneys, caused by a buildup of plaque or fatty deposits within the vessel. It often leads to hypertension, or high blood pressure, which affected 72 million Americans in 2004 (American Heart Association, 2004 data-released 2007). Renal stenting, where a wire mesh stent is inserted into the renal artery, is an increasingly common technique to relieve symptoms of renal arterial disease.

Results of Dr. Aqel's pilot study using Metricath were as follows:

- Metricath guidance resulted in adjunctive intervention in 90% of lesions

- Minimal luminal diameter (MLD) increased from 4.40+/-0.77 mm before adjunctive intervention to 5.17+/-0.82 mm (p less than 0.001) after adjunctive intervention

- Metricath MLD to the angiographic reference vessel diameter improved from 77.4+/-15.2% to 91.2+/-17.5% (p less than 0.001)

- Metricath MLD to the nominal stent diameter improved from 76.2+/-7.1% to 90.0+/-9.4% (p less than 0.001)

The Metricath System was also featured during a case presentation at the NCVH conference. Dr. David E. Allie, chief of cardiothoracic and endovascular surgery at the Cardiovascular Institute of the South, Lafayette, Louisiana, and Dr. Craig M. Walker, medical director and cardiologist at the Cardiovascular Institute of the South, Houma, Louisiana, discussed a patient with peripheral vascular disease where a Metricath Libra catheter was used to measure the popiteal artery in order to optimize interventional treatment. A group of interventional cardiologists, radiologists, vascular surgeons and other vascular care practitioners attended the discussion.

About Metricath

The Metricath System is a balloon-tipped catheter used during angioplasty procedures to treat heart and vascular disease. The catheter features a low-pressure balloon that can precisely measure within arteries and stents, helping doctors with optimal stent selection and to confirm optimal stent expansion. The Metricath Libra is cleared for use in the United States, Canada, and the European Union.

About NCVH

New Cardiovascular Horizons is the fourth largest cardiovascular conference in the United States. It has become the first and largest truly multidisciplinary conference to bring together over 3,000 cardiologists, fellows, residents, imaging professionals, cath lab techs, registered nurses, surgeons and many others to encompass the management, treatment and evaluation of all fields of medicine, with a primary focus on peripheral vascular disease and cardiovascular disease. Please visit

About Medical Ventures Corp.

Medical Ventures Corp. develops, manufactures and commercializes medical devices for the quickly growing vascular and surgical marketplace. MEV products help doctors treat a wide range of health concerns, including vascular disease and obesity. MEV products include the Metricath® vascular measurement system and PeriPatch™, a line of surgical tissue products. Medical Ventures is also a contract medical devices manufacturer. For more information, please visit

Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words "anticipates", "believes", "may", "continues", "estimates", "expects", and "will" and words of similar import, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, the following: general economic and business conditions, both nationally and in the regions in which the Company operates; technology changes; competition; changes in business strategy or development plans; the ability to attract and retain qualified personnel; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; liability and other claims asserted against the Company; and other factors referenced in the Company's filings with Canadian securities regulators. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company does not assume the obligation to update any forward-looking statements.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Contact Information